{"transactions":[{"id":718191,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":3389,"price":114.29,"value":387328.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."}],"balance_after":47179.438,"source":{"system":"sec-edgar","filing":"0001193125-26-295089","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295089/ownership.xml","form_type":"4"}},{"id":726446,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T22:00:06.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date."}],"balance_after":90000,"derivative":{"exercise_price":21.05,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-26-283139","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526283139/ownership.xml","form_type":"4"}},{"id":726445,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:00:06.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":119,"value":297500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":50195.438,"source":{"system":"sec-edgar","filing":"0001193125-26-283139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526283139/ownership.xml","form_type":"4"}},{"id":726444,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:00:06.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":109,"value":272500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":52695.438,"source":{"system":"sec-edgar","filing":"0001193125-26-283139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526283139/ownership.xml","form_type":"4"}},{"id":726443,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:00:06.000Z","date":"2026-06-25","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":21.05,"value":105250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":55195.438,"source":{"system":"sec-edgar","filing":"0001193125-26-283139","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526283139/ownership.xml","form_type":"4"}},{"id":730576,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T21:47:25.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date."}],"balance_after":95000,"derivative":{"exercise_price":21.05,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001193125-26-277766","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526277766/ownership.xml","form_type":"4"}},{"id":730575,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-06-22T21:47:25.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":99,"value":247500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":50195.438,"source":{"system":"sec-edgar","filing":"0001193125-26-277766","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526277766/ownership.xml","form_type":"4"}},{"id":730574,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-06-22T21:47:25.000Z","date":"2026-06-22","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":21.05,"value":52625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":52695.438,"source":{"system":"sec-edgar","filing":"0001193125-26-277766","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526277766/ownership.xml","form_type":"4"}},{"id":807162,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-04-16T22:30:05.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":1347,"price":90,"value":121230.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":50195.438,"source":{"system":"sec-edgar","filing":"0001193125-26-159539","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526159539/ownership.xml","form_type":"4"}},{"id":810489,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-10T20:45:41.000Z","date":"2026-04-09","kind":"exercise","planned":true,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares underlying this stock option vested on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date."}],"balance_after":97500,"derivative":{"exercise_price":21.05,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001193125-26-151393","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526151393/ownership.xml","form_type":"4"}},{"id":810488,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:45:41.000Z","date":"2026-04-10","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":87.35,"value":174700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":51542.438,"source":{"system":"sec-edgar","filing":"0001193125-26-151393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526151393/ownership.xml","form_type":"4"}},{"id":810487,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:45:41.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":89,"value":222500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":53542.438,"source":{"system":"sec-edgar","filing":"0001193125-26-151393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526151393/ownership.xml","form_type":"4"}},{"id":810486,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:45:41.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":2670,"price":87.1109,"value":232586.103,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.015 to $87.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":56042.438,"source":{"system":"sec-edgar","filing":"0001193125-26-151393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526151393/ownership.xml","form_type":"4"}},{"id":810485,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:45:41.000Z","date":"2026-04-09","kind":"sale","planned":true,"acquired":false,"shares":3094,"price":86.618,"value":267996.092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.005 to $86.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":58712.438,"source":{"system":"sec-edgar","filing":"0001193125-26-151393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526151393/ownership.xml","form_type":"4"}},{"id":810484,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:45:41.000Z","date":"2026-04-09","kind":"exercise","planned":true,"acquired":true,"shares":2500,"price":21.05,"value":52625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."}],"balance_after":61806.438,"source":{"system":"sec-edgar","filing":"0001193125-26-151393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526151393/ownership.xml","form_type":"4"}},{"id":861817,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T23:00:08.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":18450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option shall vest in fourty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date."}],"balance_after":18450,"derivative":{"exercise_price":90.1,"expiration_date":"2036-03-01","underlying":"Common Stock","underlying_shares":18450},"source":{"system":"sec-edgar","filing":"0001193125-26-091984","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091984/ownership.xml","form_type":"4"}},{"id":861816,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:00:08.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":9225,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date."}],"balance_after":59306.438,"source":{"system":"sec-edgar","filing":"0001193125-26-091984","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526091984/ownership.xml","form_type":"4"}},{"id":1174753,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-09T12:05:05.000Z","date":"2025-04-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this stock option shall vest on April 8, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":21.05,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-052310","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025052310/ownership.xml","form_type":"4"}},{"id":1174752,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-04-09T12:05:05.000Z","date":"2025-04-08","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following April 8, 2025, subject to the reporting person's continued employment through each vesting date."}],"balance_after":50081.438,"source":{"system":"sec-edgar","filing":"0000950170-25-052310","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000095017025052310/ownership.xml","form_type":"4"}}]}